



CLAIMS


1. A therapeutic agent for neurodegenerative disorders comprising, as an active ingredient, a xanthine derivative represented by formula (I):



wherein R^1 , R^2 and R^3 independently represent hydrogen, lower alkyl, lower alkenyl or lower alkynyl; R^4 represents cycloalkyl, $-(CH_2)_n-R^5$ (wherein R^5 represents substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group, and n is an integer of 0 to 4), or the following group:




wherein Y^1 and Y^2 independently represent hydrogen, halogen or lower alkyl, and Z represents substituted or unsubstituted aryl or the following group:



(wherein R^6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino, and m is an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group; and X^1 and X^2 independently represent O or S, or a pharmaceutically acceptable salt thereof.

5 3. The therapeutic agent for neurodegenerative disorders according to claim 1 or 2 comprising, as an active ingredient, the compound wherein R⁴ is the following group:



wherein Z has the same meaning as defined above, or a pharmaceutically acceptable salt thereof.

4. A method of treating neurodegenerative disorders, which comprises administering an effective dose of a xanthine derivative according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof.

5. Use of a xanthine derivative according to claims 1 to 3 or a pharmaceutically acceptable salt thereof for manufacturing a pharmaceutical composition useful for treatment of neurodegenerative disorders.

Add B1

add F4